Prognostic Impact of IGF2BP3 Expression in Patients with Surgically Resected Lung Adenocarcinoma
Prognostic Impact of IGF2BP3 Expression in Patients with Surgically Resected Lung Adenocarcinoma
复制标题
DOI：
10.1089/dna.2020.6136
复制
发表时间：
2021-01-25
影响因子：
3.1
通讯作者：
He, Jie
中科院分区：
文献类型：
--
作者：
Guo, Wei;Huai, Qilin;He, Jie
肺腺癌(LUAD)是肺癌的典型组织亚型，其死亡率和发病率一直居高不下。因此，需要更多的治疗靶点。胰岛素样生长因子2信使RNA结合蛋白(IGF2BPs)是一类RNA结合蛋白，包括IGF2BP1、IGF2BP2和IGF2BP3，被认为是N6-甲基腺苷(M6A)甲基化的阅读器，对肿瘤的发生发展有重要影响。研究表明，与IGF2BPs家族的其他成员相比，IGF2BP3在多个公共数据库中具有预测预后的潜力。本研究旨在利用IGF2BP3在多个队列中的表达数据，探讨IGF2BP3在LUAD中的表达及其预后意义。根据Oncomine数据库的6个数据集，LUAD组织中IGF2BP3的表达明显高于正常组织。在癌症基因组图谱(TCGA)、基因表达谱交互分析和基因表达总表的三个队列中，IGF2BP3在LUAD中异常高表达，并可能导致较差的预后(p<；0.05)。国家癌症研究中心中国中心的队列研究证实了IGF2BP3的预后价值，IGF2BP3的高表达与性别、肿瘤长度、分化程度和T分期显著相关(p<；0.05)。对TCGA和NCC队列的Cox回归分析一致显示IGF2BP3的表达可以独立预测LUAD患者的预后(p<；0.05)。确定了10条显著富含的标志性途径。IGF2BP3在LUAD组织中异常高表达，可导致较差的总体存活率。综上所述，IGF2BP3可能是LUAD的癌基因和潜在的预后生物标志物。
Lung adenocarcinoma (LUAD) acts as the representative histological subtype regarding lung cancer, and its mortality and morbidity remain high. Therefore, more therapeutic targets are needed. Insulin-like growth factor 2 messenger RNA-binding proteins (IGF2BPs), a class of RNA-binding proteins, including IGF2BP1, IGF2BP2, and IGF2BP3, are considered to be the "reader" of N6-methyladenosine (m6A) methylation and remarkably affects cancer occurrence and development. Studies have shown that IGF2BP3 has prognostic potential in multiple public databases compared with other members of the IGF2BPs family. This research aims to use the expression data of IGF2BP3 in multiple cohorts to explore the expression as well as prognostic significance of IGF2BP3 in LUAD. Based on the six datasets from the Oncomine database, LUAD tissue presented obviously higher IGF2BP3 expression relative to normal tissue. In the three cohorts of The Cancer Genome Atlas (TCGA), Gene expression profiling interactive analysis, and Gene Expression Omnibus, IGF2BP3 was abnormally highly expressed in LUAD, and it could lead to a weaker prognosis (p < 0.05). The cohort from National Cancer Center of China (NCC) verified the prognostic value of IGF2BP3, and the high IGF2BP3 expression could be remarkably related to gender, tumor length, differentiation, and T stage (p < 0.05). Cox regression analysis of TCGA and NCC cohorts consistently showed that IGF2BP3 expression could serve for independently predicting the prognosis of LUAD patients (p < 0.05). Ten hallmark pathways with significant enrichment were identified. IGF2BP3 is abnormally highly expressed in LUAD tissue, and can lead to worse overall survival. In summary, IGF2BP3 may be an oncogene and potential prognostic biomarker of LUAD.